Tailong Investment
VC Fund
Tailong Investment is an Investment firm.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Tailong Investment invests in
Stages Tailong Investment invests in
Countries Tailong Investment invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sun Fa
|
|||
|
Sun Jun
|
|||
3 more contacts available
Investment Focus
Industry
- Medical 10 (63%)
- Health Care 8 (50%)
- Biotechnology 8 (50%)
- Pharmaceutical 5 (31%)
- Medical Device 4 (25%)
Stage
- Series A 8 (50%)
- Series B 4 (25%)
- Seed 2 (13%)
- Angel 1 (6%)
- Series C 1 (6%)
Country
- China 10 (63%)
- Switzerland 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sun Fa
Executive Director
|
Executive Director | Total investments: 1 | Find email | |
|
Sun Jun
Executive Director
|
Executive Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Delova Biotech specializes in the field of pain treatment. It uses the company's rich R&D experience and special preparation technology platform to improve existing drugs and conduct research and development of improved new analgesics in China and the United States. | $88.6M / Series C / Jul 22, 2026 | |
|
|
Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | $28.8M / Series A / Jan 26, 2026 | |
|
|
ROBO Medical is a medical robot research and development company. | Series B / Jul 18, 2025 | |
|
|
Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. The company engages in the development of global CAR-NK and tiNK cell therapy drugs and is committed to solving the treatment of clinically unmet diseases. | $13.5M / Series A / Jan 21, 2025 | |
|
|
Mainstream Bio is a biotechnology company grounded in research, specializing in the development of innovative peptide therapeutics 2.0. | Series A / Jan 14, 2025 | |
|
|
Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development. | $100M / Angel / Dec 24, 2024 | |
|
|
Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development. | $13.7M / Seed / Dec 24, 2024 | |
|
C Ray Therapeutics
|
C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020. | $100M / Series A / Nov 16, 2024 | |
|
|
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China. | $14M / Series B / Oct 21, 2024 | |
|
|
BiyoPharma focuses on the research and development of innovative drugs for neurological diseases, including episodic and chronic migraines, through international technology platforms and improved treatment options. | Seed / Apr 26, 2024 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Tailong Investment invest in?
Tailong Investment invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tailong Investment?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tailong Investment?
The team at Tailong Investment includes Sun Fa (Executive Director) and Sun Jun (Executive Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!